Agreement grants Eterna rights to license up to four next-generation iPS cell derived NK and T cell cancer therapies License terms include an upfront license […]
Phase 2 clinical trial for OXE103 for the treatment of concussion is being conducted at University of Kansas Medical Center, Kansas City, Kansas Enrolling highly […]